Pipeline

Hemoglobinopathies

Hemoglobinopathies

 
Research
Ind-Enabling
Clinical
Approved
 
  • * Exagamglogene Autotemcel (exa-cel): Sickle cell disease (SCD)
    •  
    •  
    •  
    •  

    Description: Autologous, ex vivo CRISPR/Cas9 gene-edited therapy in which aims to edit a patient’s own hematopoietic stem cells to produce fetal hemoglobin in red blood cells. Exa-cel, a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, has now been approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. Vertex is the manufacturer and exclusive license holder of exa-cel.

    Structure: Collaboration with Vertex

  • * Exagamglogene Autotemcel (exa-cel): β-thalassemia
    •  
    •  
    •  
    •  

    Description: Autologous, ex vivo CRISPR/Cas9 gene-edited therapy in which aims to edit a patient’s own hematopoietic stem cells to produce fetal hemoglobin in red blood cells. Exa-cel, a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, has now been approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. Vertex is the manufacturer and exclusive license holder of exa-cel.

    Structure: Collaboration with Vertex

  • Next-generation conditioning
    •  
    •  
    •  
    •  

    Description: Targeted conditioning agent to improve the safety of hematopoietic stem cell transplant

    Structure: Wholly owned (collaboration with Vertex for applications in β-thalassemia and SCD)

  • In vivo editing of HSCs
    •  
    •  
    •  
    •  

    Description: Enabling delivery of CRISPR/Cas9 to hematopoietic stem cells (HSCs) in vivo to bypass the need for ex vivo gene editing and hematopoietic stem cell transplant

    Structure: Wholly owned (collaboration with Vertex for applications in β-thalassemia and SCD)

Screen Shot 2023 11 16 at 8 15 57 AM

*Currently approved in some countries for certain eligible people.

Immuno oncology

Immuno-Oncology

 
Research
Ind-Enabling
Clinical
Approved
 
  • CTX112: Anti-CD19 allogeneic CAR T
    •  
    •  
    •  
    •  

    Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of CD19+ malignancies and autoimmune diseases that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

    Structure: Wholly owned

  • CTX131: Anti-CD70 allogeneic CAR T
    •  
    •  
    •  
    •  

    Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for the treatment of solid tumors and hematological malignancies that incorporates novel edits designed to enhance CAR T potency and reduce CAR T exhaustion

    Structure: Wholly owned

  • Anti-CD70 allogeneic CAR-NK
    •  
    •  
    •  
    •  

    Description: Investigational allogeneic CRISPR/Cas9 gene-edited CAR-NK cell therapy

    Structure: Collaboration with Nkarta

  • CTX121: Anti-BCMA allogeneic CAR-T
    •  
    •  
    •  
    •  

    Description: Allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy in development for multiple myeloma that incorporates additional edits designed to enhance CAR T potency and reduce CAR T exhaustion

    Structure: Wholly owned

  • Anti-CD83 autologous CAR-T
    •  
    •  
    •  
    •  

    Description: Autologous CAR T cell therapy in development for AML and other oncology and autoimmune indications

    Structure: Collaboration with Moffitt Cancer Center (CRISPR retains commercial rights)

  • Anti-GPC3 autologous CAR-T
    •  
    •  
    •  
    •  

    Description: Autologous CRISPR/Cas9 gene-edited CAR T cell therapy in development for hepatocellular carcinoma

    Structure: Collaboration with Roswell Park Comprehensive Cancer Center (CRISPR retains commercial rights)

Regenative Medicine

Regenerative Medicine

 
Research
Ind-Enabling
Clinical
Approved
 
  • VCTX210: Type I diabetes mellitus
    •  
    •  
    •  
    •  

    Description: Allogeneic, gene-edited, immune-evasive, stem cell-derived beta-cell replacement therapy

    Structure: Collaboration with ViaCyte

  • VCTX211: Type I diabetes mellitus
    •  
    •  
    •  
    •  

    Description: Investigational allogeneic, gene-edited, immune-evasive, stem cell-derived beta-cell replacement therapy with additional gene edits that aim to further enhance cell fitness

    Structure: Collaboration with ViaCyte

  • VCTX212: Type I/II diabetes mellitus
    •  
    •  
    •  
    •  

    Description: Investigational allogeneic, gene-edited, immune-evasive, stem cell-derived beta-cell replacement therapy with additional gene edits that aim to further enhance cell fitness

    Structure: Collaboration with ViaCyte

In Vivo

In Vivo Approaches

 
Research
Ind-Enabling
Clinical
Approved
 

Download the CRISPR Therapeutics Corporate Presentation


CTX112™, CTX121™, CTX131™, CTX310™, CTX320™, CTX330™, VCTX210™, VCTX211™ and VCTX212™ are trademarks and registered trademarks of CRISPR Therapeutics AG.

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.

Continue